Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2017, Article ID 4812637, 11 pages
https://doi.org/10.1155/2017/4812637
Review Article

The Evolution of Prognostic Factors in Multiple Myeloma

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Correspondence should be addressed to Amr Hanbali; as.ude.crhsfk@ilabnaha

Received 17 October 2016; Revised 22 January 2017; Accepted 5 February 2017; Published 21 February 2017

Academic Editor: David H. Vesole

Copyright © 2017 Amr Hanbali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. P. Carbone, L. E. Kellerhouse, and E. A. Gehan, “Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients,” The American Journal of Medicine, vol. 42, no. 6, pp. 937–948, 1967. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Costa, R. L. Engle, A. Schilling et al., “Melphalan and prednisone: an effective combination for the treatment of multiple myeloma,” The American Journal of Medicine, vol. 54, no. 5, pp. 589–599, 1973. View at Publisher · View at Google Scholar · View at Scopus
  3. B. G. M. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma,” Cancer, vol. 36, pp. 842–854, 1975. View at Google Scholar
  4. P. R. Greipp, J. S. Miguel, B. G. M. Dune et al., “International staging system for multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3412–3420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Merlini, J. G. Waldenstrom, and S. D. Jayakar, “A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients,” Blood, vol. 55, no. 6, pp. 1011–1019, 1980. View at Google Scholar · View at Scopus
  6. R. Bataille, B. G. M. Durie, J. Grenier, and J. Sany, “Prognostic factors and staging in multiple myeloma: a reappraisal,” Journal of Clinical Oncology, vol. 4, no. 1, pp. 80–87, 1986. View at Google Scholar · View at Scopus
  7. J. Blade, C. Rozman, F. Cervantes, J.-C. Reverter, and E. Montserrat, “A new prognostic system for multiple myeloma based on easily available parameters,” British Journal of Haematology, vol. 72, no. 4, pp. 507–511, 1989. View at Publisher · View at Google Scholar · View at Scopus
  8. Medical Research Council's Working Party on Leukemia in Adults, “Prognostic features in the third MRC myelomatosis trial,” British Journal of Cancer, vol. 42, no. 6, pp. 831–840, 1980. View at Google Scholar
  9. P. N. Hari, M.-J. Zhang, V. Roy et al., “Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant,” Leukemia, vol. 23, no. 8, pp. 1528–1534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Palumbo, H. Avet-Loiseau, S. Oliva et al., “Revised international staging system for multiple myeloma: a report from international myeloma working group,” Journal of Clinical Oncology, vol. 33, no. 26, pp. 2863–2869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kumar, S. V. Rajkumar, P. R. Greipp, and T. E. Witzig, “Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments,” American Journal of Hematology, vol. 77, no. 1, pp. 7–11, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. R. Greipp, J. A. Lust, W. M. O'Fallon, J. A. Katzmann, T. E. Witzig, and R. A. Kyle, “Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma,” Blood, vol. 81, no. 12, pp. 3382–3387, 1993. View at Google Scholar · View at Scopus
  13. D. P. Steensma, M. A. Gertz, P. R. Greipp et al., “A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death,” Blood, vol. 97, no. 8, pp. 2522–2523, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Li, L. Chen, X. Gao et al., “Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma,” Leukemia and Lymphoma, vol. 52, no. 2, pp. 260–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Keats, T. Reiman, C. A. Maxwell et al., “In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression,” Blood, vol. 101, no. 4, pp. 1520–1529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Gertz, M. Q. Lacy, A. Dispenzieri et al., “Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy,” Blood, vol. 106, no. 8, pp. 2837–2840, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Jaksic, S. Trudel, H. Chang et al., “Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7069–7073, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Moreau, M. Attal, F. Garban et al., “Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials,” Leukemia, vol. 21, no. 9, pp. 2020–2024, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. D. Shaughnessy Jr., F. Zhan, B. E. Burington et al., “Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1,” Blood, vol. 109, no. 6, pp. 2276–2284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. C. Gutiérrez, M. V. Castellanos, M. L. Martín et al., “Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis,” Leukemia, vol. 21, no. 1, pp. 143–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Kalff and A. Spencer, “The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies,” Blood Cancer Journal, vol. 2, article no. 37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Hébraud, D. Caillot, J. Corre et al., “The translocation t(4;14) can be present only in minor subclones in multiple myeloma,” Clinical Cancer Research, vol. 19, no. 17, 2013. View at Google Scholar
  23. J. D. Hoyer, C. A. Hanson, R. Fonseca, P. R. Greipp, G. W. Dewald, and P. J. Kurtin, “The (11;14)(q13;q32) translocation in multiple myeloma: A Morphologic and Immunohistochemical Study,” American Journal of Clinical Pathology, vol. 113, no. 6, pp. 831–837, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Fonseca, E. A. Blood, M. M. Oken et al., “Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients,” Blood, vol. 99, no. 10, pp. 3735–3741, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Garand, H. Avet-Loiseau, F. Accard, P. Moreau, J. L. Harousseau, and R. Bataille, “t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma,” Leukemia, vol. 17, no. 10, pp. 2032–2035, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Avet-Loiseau, R. Garand, L. Lodé, J.-L. Harousseau, and R. Bataille, “Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants,” Blood, vol. 101, no. 4, pp. 1570–1571, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Robillard, H. Avet-Loiseau, R. Garand et al., “CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma,” Blood, vol. 102, no. 3, pp. 1070–1071, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Moreau, T. Facon, X. Leleu et al., “Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy,” Blood, vol. 100, no. 5, pp. 1579–1583, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Fonseca, T. E. Witzig, M. A. Gertz et al., “Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases,” British Journal of Haematology, vol. 101, no. 2, pp. 296–301, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Parkins, M. Boll, S. J. M. O'Connor, A. C. Rawstron, and R. G. Owen, “Extramedullary plasmacytoma with a t(11;14)(q13;q32) and aggressive clinical course,” Leukemia and Lymphoma, vol. 51, no. 7, pp. 1360–1362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. D. Shaughnessy, F. Zhan, B. E. Burington et al., “A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1,” Blood, vol. 109, no. 6, pp. 2276–2284, 2007. View at Publisher · View at Google Scholar
  32. H.-J. Shin, K. Kim, J.-J. Lee et al., “The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma,” Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 4, pp. 227–235, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. G. An, Y. Xu, L. Shi et al., “T(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome,” Leukemia Research, vol. 37, no. 10, pp. 1251–1257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Binder, S. V. Rajkumar, R. P. Ketterling et al., “Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma,” Blood Cancer Journal, vol. 6, 2016. View at Publisher · View at Google Scholar
  35. G. P. Kaufman, M. A. Gertz, A. Dispenzieri et al., “Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma,” Leukemia, vol. 30, no. 3, pp. 633–639, 2015. View at Publisher · View at Google Scholar
  36. J. R. Mikhael, D. Dingli, V. Roy et al., “Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013,” Mayo Clinic Proceedings, vol. 88, no. 4, pp. 360–376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Iriuchishima, T. Saitoh, H. Handa et al., “A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents,” European Journal of Haematology, vol. 94, no. 2, pp. 145–151, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Moreau, M. Cavo, P. Sonneveld et al., “Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death,” Journal of Clinical Oncology, vol. 32, no. 20, pp. 2173–2180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Li, Y. Xu, S. Deng et al., “MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma,” Oncotarget, vol. 6, no. 35, pp. 38270–38282, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Wang, H. Wang, H. Chen et al., “Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma,” Oncotarget, vol. 6, no. 38, pp. 41228–41236, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. S.-H. Jung, J. S. Kim, W. S. Lee et al., “Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen,” Annals of Hematology, vol. 95, no. 1, pp. 55–61, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Zhou, H. Zhao, Z. Wang et al., “Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma,” Journal of Experimental and Clinical Cancer Research, vol. 34, article 102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Lee, H. Lee, S. Y. Moon et al., “Adverse prognostic impact of bone marrow microvessel density in multiple myeloma,” Annals of Laboratory Medicine, vol. 35, no. 6, pp. 563–569, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Ma, Q.-F. Yu, X.-Y. Liu et al., “Expression of N-cadherin in patients with multiple myeloma and its clinical significance,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 23, no. 4, pp. 1044–1048, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. G. D. Lullo, M. Marcatti, S. Heltai et al., “Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival,” OncoImmunology, vol. 4, no. 5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Li, M. Hao, X. Feng et al., “Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma,” Leukemia Research, vol. 39, no. 7, pp. 793–799, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Bolomsky, D. Hose, M. Schreder et al., “Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma,” Journal of Hematology and Oncology, vol. 8, article 10, Article ID 13045, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Jung, J. Roh, H. Lee et al., “Autophagic markers BECLIN 1 and LC3 are associated with prognosis of multiple myeloma,” Acta Haematologica, vol. 134, no. 1, pp. 17–24, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. T. N. Trotter, M. Li, Q. Pan et al., “Myeloma cell-derived Runx2 promotes myeloma progression in bone,” Blood, vol. 125, no. 23, pp. 3598–3608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Vande Broek, K. Vanderkerken, B. Van Camp, and I. Van Riet, “Extravasation and homing mechanisms in multiple myeloma,” Clinical and Experimental Metastasis, vol. 25, no. 4, pp. 325–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Avet-Loiseau, F. Malard, L. Campion et al., “Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?” Blood, vol. 117, no. 6, pp. 2009–2011, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Nair, F. Van Rhee, J. D. Shaughnessy Jr. et al., “Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance,” Blood, vol. 115, no. 21, pp. 4168–4173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Fonseca, “Clinical and biologic implications of recurrent genomic aberrations in myeloma,” Blood, vol. 101, no. 11, pp. 4569–4575, 2003. View at Publisher · View at Google Scholar
  54. G. Tricot, B. Barlogie, S. Jagannath et al., “Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities,” Blood, vol. 86, no. 11, pp. 4250–4256, 1995. View at Google Scholar · View at Scopus
  55. N. Zojer, R. Königsberg, J. Ackermann et al., “Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization,” Blood, vol. 95, no. 6, pp. 1925–1930, 2000. View at Google Scholar · View at Scopus
  56. N. Worel, H. Greinix, J. Ackermann et al., “Deletion of chromosome 13q14 detected by FISH has prognostic impact on survival after high-dose therapy in patients with multiple myeloma,” Annals of Hematology, vol. 80, pp. 345–348, 2001. View at Google Scholar
  57. R. Fonseca, D. Harrington, M. M. Oken et al., “Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: An Eastern Cooperative Oncology Group Study,” Cancer Research, vol. 62, no. 3, pp. 715–720, 2002. View at Google Scholar · View at Scopus
  58. H. Kaufmann, E. Krömer, T. Nösslinger et al., “Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma,” European Journal of Haematology, vol. 71, no. 3, pp. 179–183, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. V. Sagaster, H. Ludwig, H. Kaufmann et al., “Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion,” Leukemia, vol. 21, no. 1, pp. 164–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Lodé, M. Eveillard, V. Trichet et al., “Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma,” Haematologica, vol. 95, no. 11, pp. 1973–1976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. W. Xiong, X. Wu, S. Starnes et al., “An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma,” Blood, vol. 112, no. 10, pp. 4235–4246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Drach, J. Ackermann, E. Fritz et al., “Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy,” Blood, vol. 92, no. 3, pp. 802–809, 1998. View at Google Scholar · View at Scopus
  63. B. Lucani, G. Papini, M. Bocchia, and A. Gozzetti, “P53 and molecular genetics of multiple myeloma,” Journal of Blood Disorders, vol. 1, no. 1, p. 3, 2014. View at Google Scholar
  64. A. D. Panani, A. D. Ferti, C. Papaxoinis, S. A. Raptis, and C. Roussos, “Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor,” Anticancer Research, vol. 24, no. 6, pp. 4141–4146, 2004. View at Google Scholar · View at Scopus
  65. Y. Marzin, D. Jamet, N. Douet-Guilbert et al., “Chromosome 1 abnormalities in multiple myeloma,” Anticancer Research, vol. 26, no. 2, pp. 953–959, 2006. View at Google Scholar · View at Scopus
  66. M. H. Qazilbash, R. M. Saliba, B. Ahmed et al., “Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant,” Biology of Blood and Marrow Transplantation, vol. 13, no. 9, pp. 1066–1072, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Caltagirone, M. Ruggeri, S. Aschero et al., “Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies,” Haematologica, vol. 99, no. 10, pp. 1611–1617, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Zhan, J. Hardin, B. Kordsmeier et al., “Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells,” Blood, vol. 99, no. 5, pp. 1745–1757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Zhan, Y. Huang, S. Colla et al., “The molecular classification of multiple myeloma,” Blood, vol. 108, no. 6, pp. 2020–2028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Broyl, D. Hose, H. Lokhorst et al., “Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients,” Blood, vol. 116, no. 14, pp. 2543–2553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. W. J. Chng, S. Kumar, S. VanWier et al., “Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling,” Cancer Research, vol. 67, no. 7, pp. 2982–2989, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. O. Decaux, L. Lodé, F. Magrangeas et al., “Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4798–4805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Kuiper, A. Broyl, Y. De Knegt et al., “A gene expression signature for high-risk multiple myeloma,” Leukemia, vol. 26, no. 11, pp. 2406–2413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Kuiper, M. Van Duin, M. H. Van Vliet et al., “Prediction of high- and low-risk multiple myeloma based on gene expression and the international staging system,” Blood, vol. 126, no. 17, pp. 1996–2004, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Dimopoulos, R. Kyle, J. P. Fermand et al., “Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3,” Blood, vol. 117, no. 18, pp. 4701–4705, 2011. View at Publisher · View at Google Scholar
  76. S. V. Rajkumar, R. A. Kyle, T. M. Therneau et al., “Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance,” Blood, vol. 106, no. 3, pp. 812–817, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. J. T. Larsen, S. K. Kumar, A. Dispenzieri, R. A. Kyle, J. A. Katzmann, and S. V. Rajkumar, “Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma,” Leukemia, vol. 27, no. 4, pp. 941–946, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Dingli, R. A. Kyle, S. V. Rajkumar et al., “Immunoglobulin free light chains and solitary plasmacytoma of bone,” Blood, vol. 108, no. 6, pp. 1979–1983, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Jagannath, “Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology,” Clinical Lymphoma and Myeloma, vol. 7, no. 8, pp. 518–523, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Kraj, “Immunoglobulin heavy chain/light chain pairs (Hlc, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies,” Advances in Clinical and Experimental Medicine, vol. 23, no. 1, pp. 127–133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Koulieris, P. Panayiotidis, S. J. Harding et al., “Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma,” Experimental Hematology & Oncology, vol. 1, no. 9, 2012. View at Publisher · View at Google Scholar
  82. F. E. Lecouvet, B. C. Vande Berg, J. Malghem, and B. E. Maldague, “Magnetic resonance and computed tomography imaging in multiple myeloma,” Seminars in Musculoskeletal Radiology, vol. 5, no. 1, pp. 43–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology, Multiple myeloma, V.1.2016.
  84. A. Baur-Melnyk, S. Buhmann, H. R. Dürr, and M. Reiser, “Role of MRI for the diagnosis and prognosis of multiple myeloma,” European Journal of Radiology, vol. 55, no. 1, pp. 56–63, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. M. A. Dimopoulos, J. Hillengass, S. Usmani et al., “The role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group,” Journal of Clinical Oncology, vol. 33, no. 6, pp. 657–664, 2015. View at Publisher · View at Google Scholar
  86. M. A. Bredella, L. Steinbach, G. Caputo, G. Segall, and R. Hawkins, “Value of FDG PET in the assessment of patients with multiple myeloma,” American Journal of Roentgenology, vol. 184, no. 4, pp. 1199–1204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Moreau, “PET-CT in MM: a new definition of CR,” Blood, vol. 118, no. 23, pp. 5984–5985, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Terpos, M. Kleber, M. Engelhardt et al., “European myeloma network guidelines for the management of multiple myeloma-related complications,” Haematologica, vol. 100, no. 10, pp. 1254–1266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  89. M. J. Pianko, E. Terpos, G. D. Roodman et al., “Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease,” Clinical Cancer Research, vol. 20, no. 23, pp. 5888–5897, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. G. S. Nowakowski, T. E. Witzig, D. Dingli et al., “Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma,” Blood, vol. 106, no. 7, pp. 2276–2279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. P. R. Greipp, T. Leong, J. M. Bennett et al., “Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group,” Blood, vol. 91, no. 7, pp. 2501–2507, 1998. View at Google Scholar · View at Scopus
  92. W. J. Chng, A. Dispenzieri, C.-S. Chim et al., “IMWG consensus on risk stratification in multiple myeloma,” Leukemia, vol. 28, no. 2, pp. 269–277, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. F. Gay, A. Larocca, P. Wijermans et al., “Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients,” Blood, vol. 117, no. 11, pp. 3025–3031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. J. J. Lahuerta, M. V. Mateos, J. Martínez-López et al., “Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5775–5782, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. B. G. Durie, J. L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Google Scholar
  96. S. Vincent Rajkumar, J.-L. Harousseau, B. Durie et al., “Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1,” Blood, vol. 117, no. 18, pp. 4691–4695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Paiva, J. J. M. Van Dongen, and A. Orfao, “New criteria for response assessment: role of minimal residual disease in multiple myeloma,” Blood, vol. 125, no. 20, pp. 3059–3068, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. J. F. S. San Miguel, J. Almeida, G. Mateo et al., “Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome,” Blood, vol. 99, no. 5, pp. 1853–1856, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Paiva, M. B. Vidriales, J. Cerveró et al., “Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation,” Blood, vol. 112, no. 10, pp. 4017–4023, 2008. View at Google Scholar
  100. N. Puig, M. E. Sarasquete, A. Balanzategui et al., “Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry,” Leukemia, vol. 28, no. 2, pp. 391–397, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Martinez-Lopez, J. J. Lahuerta, F. Pepin et al., “Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma,” Blood, vol. 123, no. 20, pp. 3073–3079, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Bladé, C. Fernández de Larrea, L. Rosiñol, M. T. Cibeira, R. Jiménez, and R. Powles, “Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach,” Journal of Clinical Oncology, vol. 29, no. 28, pp. 3805–3812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Hillengass, T. Bäuerle, R. Bartl et al., “Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology,” British Journal of Haematology, vol. 153, no. 6, pp. 721–728, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. B. Paiva, M. B. Vidriales, J. Cerveró et al., “Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation,” Blood, vol. 112, no. 10, pp. 4017–4023, 2008. View at Publisher · View at Google Scholar
  105. A. C. Rawstron, J. A. Child, R. M. de Tute et al., “Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study,” Journal of Clinical Oncology, vol. 31, no. 20, pp. 2540–2547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. M. E. Gore, C. Viner, M. Meldrum et al., “Intensive treatment of multiple myeloma and criteria for complete remission,” The Lancet, vol. 334, no. 8668, pp. 879–882, 1989. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Bladé, D. Samson, D. Reece et al., “Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation,” British Journal of Haematology, vol. 102, no. 5, pp. 1115–1123, 1998. View at Publisher · View at Google Scholar · View at Scopus
  108. B. G. Durie, J. L. Harousseau, J. S. San Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Google Scholar